疑难病杂志2012，Vol.11Issue(9)：671-673,3.DOI:10.3969/j.issn.1671-6450.2012.09.008
淋巴瘤患者化疗期间预防性抗乙肝病毒治疗的策略分析
The prophylactic anti-HBV treatment strategy for lymphoma patients during Chemotherapy
刘松涛 1付丽 2王昭 2崔华 2杨凌志 2王婷婷 2黄达永2
作者信息
- 1. 100069,首都医科大学附属北京佑安医院重症肝病科
- 2. 100050,首都医科大学附属北京友谊医院血液科
- 折叠
摘要
Abstract
Objective To analyse the necessity and drug choice of prophylactic anti-HBV treatment in lymphoma patients with chronic hepatitis B virus infection. Methods Retrospective analyzed the initial presentation of 23 cases lymphoma patients with chronic hepatitis B virus infection, and investigate the prophylactic drug choice and effectiveness. Results 22 cases were selected the prophylactic drug in all of the 23 cases. One case died because of secondary acute lymphoblastic leukemia and others completed the chemotherapy. ALT increased in 6 cases during treatment. It was gradually reduced to normal level after switching to entecavir in one case and maintaining the original program in others. There were 15 HBV-DNA positive cases before chemotherapy, 5 cases maintained positive to the end of chemotherapy and others converted to negative after 1 to 3 months. There were 8 HBV-DNA negative cases before chemotherapy, 4 cases maintained negative to the end of chemotherapy and others occurred to viral replication. Conclusion The prophylactic anti-HBV treatment strategy was necessary when chemotherapy were applied to lymphoma patients with chronic HBV infection. The lamivudine could be used continually if the HBV-DNA was negative or had a good response within three months. But it's necessary to monitor HBV-DNA and ALT. The entecavir would be the better choice for the initial treatment if patient condition was allowed.关键词
淋巴瘤/乙肝病毒/化疗Key words
Lymphoma/ Hepatitis B virus/ Chemotherapy引用本文复制引用
刘松涛,付丽,王昭,崔华,杨凌志,王婷婷,黄达永..淋巴瘤患者化疗期间预防性抗乙肝病毒治疗的策略分析[J].疑难病杂志,2012,11(9):671-673,3.
